Drug Development
Lantern Pharma CEO Details AI Platform's Role in Accelerating Cancer Drug Development
Lantern Pharma is using artificial intelligence to significantly reduce the time and cost of oncology drug development while expanding treatment options for cancer patients.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.
Soligenix Advances Psoriasis Treatment SGX302 with Promising Early Clinical Results
Soligenix is progressing its phase 2a clinical trial of SGX302 for psoriasis treatment, showing encouraging safety and biological activity data that positions the therapy to address a $67 billion global market opportunity.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.
Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Sapu Nano Announces First Human Trial of Injectable Everolimus Formulation for Breast Cancer
Sapu Nano has revealed initial human clinical trials for Sapu-003, an intravenous formulation of Everolimus that could offer improved bioavailability and efficacy compared to oral versions for breast cancer treatment.
NanoViricides Reports Promising Anti-Measles Results for Broad-Spectrum Antiviral Candidate NV-387
NanoViricides' experimental drug NV-387 demonstrates strong efficacy against Measles in preclinical studies, potentially addressing the critical gap in approved treatments for the resurgent viral disease.
NanoViricides to Present Antiviral Pipeline Updates at PODD 2025 Conference
NanoViricides will showcase its broad-spectrum antiviral drug platform at the upcoming PODD 2025 conference, highlighting progress toward Phase II trials for its lead candidate NV-387 targeting multiple respiratory viruses and MPox.
Lantern Pharma Partners with Hoth Therapeutics to Deploy AI Platform for Blood-Brain Barrier Prediction
Lantern Pharma's AI platform PredictBBB.ai, which boasts 94% accuracy in predicting drug penetration of the blood-brain barrier, is being deployed through a partnership with Hoth Therapeutics to accelerate neurological drug development.
Lantern Pharma to Present AI-Driven Oncology Pipeline at ThinkEquity Conference
Lantern Pharma will present its AI-powered cancer drug development platform and pipeline at the ThinkEquity Conference, highlighting how artificial intelligence is transforming oncology research and potentially delivering life-changing therapies to patients worldwide.
Branded Legacy Advances FDA Pathway for Low-Cost Intranasal Naloxone Alternative
Branded Legacy's subsidiary BioLegacy Evaluative Group is preparing FDA submission materials for a proprietary intranasal naloxone spray that aims to replicate Narcan's performance while reducing costs and improving global accessibility to opioid overdose reversal medication.
Kairos Pharma Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Kairos Pharma announced positive interim Phase 2 data showing ENV-105 combined with apalutamide achieved clinical benefit in 86% of metastatic castration-resistant prostate cancer patients, potentially addressing treatment resistance in advanced disease.
Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has closed a $6 million registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
NanoViricides' Dual-Track Clinical Strategy for NV-387 Antiviral Drug Highlighted in Analyst Report
NanoViricides is advancing its broad-spectrum antiviral drug candidate NV-387 through a dual-track clinical development strategy targeting both MPox and respiratory viral infections, with potential implications for global pandemic preparedness and biodefense funding opportunities.
Lantern Pharma Executives Discuss AI's Potential to Transform CNS Oncology Drug Development
Lantern Pharma's leadership explores how artificial intelligence can significantly reduce the time and cost of developing central nervous system cancer treatments, potentially accelerating patient access to new therapies.
Soligenix Expands European Medical Advisory Board to Advance CTCL Treatment Development
Soligenix is strengthening its European medical advisory board and advancing Phase 3 clinical trials for HyBryte, a potential new treatment for cutaneous T-cell lymphoma that addresses significant unmet medical needs in European patients.
Oncotelic's Injectable Everolimus Shows Promise for Dramatically Improved Breast Cancer Treatment
Oncotelic Therapeutics has received clearance to begin Phase 1 clinical trials for Sapu003, an injectable form of Everolimus that could increase drug bioavailability from 10% to up to 100%, potentially transforming breast cancer treatment efficacy.
TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline
TransCode Therapeutics has acquired Polynoma and secured $25 million from CK Life Sciences to advance its Phase 2 trial of TTX-MC138 and Phase 3-ready melanoma vaccine seviprotimut-L, positioning the company to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.
Oncotelic Therapeutics Announces Phase 1 Trial Enrollment for Novel Intravenous Everolimus Formulation in Australia
Oncotelic Therapeutics has opened enrollment for the first clinical trial of Sapu-003, an intravenous Deciparticle formulation of everolimus that represents a significant advancement in mTOR-targeted cancer therapy delivery for patients with advanced breast cancer and other malignancies.
Lantern Pharma's AI Platform Helps Hoth Therapeutics Accelerate Drug Development
Hoth Therapeutics is using Lantern Pharma's PredictBBB.ai platform to streamline drug candidate selection by predicting blood-brain barrier penetration with 94% accuracy, potentially accelerating development of neurological treatments.
FDA Guidance Accelerates Lantern Pharma's Pediatric Brain Cancer Therapy Development
Lantern Pharma received FDA guidance that will help advance its LP-184/STAR-001 therapy for rare pediatric brain cancers toward clinical trials planned for 2026, representing significant progress in treating conditions with limited options.
Scorpion Venom Compound Shows Promise in Brain Cancer Treatment Research
Researchers are exploring how scorpion venom compounds could revolutionize brain tumor treatment by helping the immune system target glioblastoma more effectively.
Lantern Pharma Champions AI-Driven Reform of 'Broken' Biotech Model at Industry Summit
Lantern Pharma's advocacy for AI platforms to streamline drug development addresses critical industry inefficiencies, potentially accelerating cancer treatments and reducing costs.
Soligenix Advances HyBryte Treatment for Cutaneous T-Cell Lymphoma with FLASH Trial Results
Soligenix is strengthening its position in CTCL treatment through promising results from its HyBryte FLASH studies, representing significant progress toward establishing a new standard of care in an underserved therapeutic area.
Cybin Advances Neuropsychiatry Pipeline with Key Clinical Milestones and Extended IP Protection
Cybin Inc. is progressing multiple late-stage clinical programs for mental health treatments, with upcoming data readouts and regulatory advancements that could significantly impact the neuropsychiatry treatment landscape.
Oncotelic's Joint Venture Sapu Nano Receives Approval for Phase 1 Trial of Injectable Everolimus for Breast Cancer
Sapu Nano's approval to begin Phase 1 clinical trials for an injectable version of Everolimus represents a potential breakthrough in breast cancer treatment by enabling full drug absorption compared to the oral version's limited 10% bioavailability.